Jasper Therapeutics Inc

NASDAQ:JSPRUnited States

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Contact Information

Headquarters

2200 Bridge Pkwy Suite #102REDWOOD CITY, CA, United States 94065

Phone

650-549-1400

Fax

302-636-5454

Executives

Chairman of the Board

Thomas Wiggans

President, Chief Executive Officer, Director

Ronald Martell

Chief Financial Officer, Corporate Secretary

Herb Cross

Chief Operating Officer

Jeetinder Mahal

Director

Scott Brun